| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Chf Clinical Develop Officer | EVP, Chf Clinical Develop Offc
1 company
Eugene Schneider is EVP, Chf Clinical Develop Officer at IONS. Eugene Schneider's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $3.1M at current prices.
Historically, Eugene Schneider's trades have earned a middling insider score of 63/100 across 14 rated trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of -13.2%.
The IONS filings lean toward selling, a net 131,225 shares.
Eugene Schneider has 26 Form 4 filings on record from January 2021 to June 2026, all as EVP, Chf Clinical Develop Officer at Ionis Pharmaceuticals (IONS), 2021–2026.
The 52 reported transactions were 17 option or other derivative awards, 15 open-market sales, 12 option exercises and 4 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 14 sales worth about $7.9M.
The largest open-market sale was 26,000 shares of IONS at an average $81.05 on June 26, 2026, about $2.1M.
6 of the 12 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 6 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP, Chf Clinical Develop Officer | Sale+OE10b5-1 | 26,000 | $81.05 | $2,107,196.00 | -25.2% | -46.0% | - | |
| Mar 19, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP, Chf Clinical Develop Officer | Sell10b5-1 | 5,812 | $70.97 | $412,486.36 | -8.3% | +4.2% | - | |
| Jan 30, 2026 | IONS Ionis Pharmaceuticals Inc | EVP, Chf Clinical Develop Officer | Sell | 6,179 | $83.45 | $515,629.52 | -8.1% | -9.6% | - | |
| Jan 16, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP, Chf Clinical Develop Officer | Sale+OE | 9,302 | $75.59 | $703,138.18 | -12.7% | -1.4% | - | |
| Sep 3, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Chf Clinical Develop Officer | Sale+OE10b5-1 | 19,658 | $60.81 | $1,195,420.87 | -27.6% | +34.4% | -3.9% | |
| Aug 4, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Chf Clinical Develop Officer | Sell10b5-1 | 9,549 | $42.80 | $408,701.02 | -15.6% | +69.5% | +26.7% | |
| Jan 31, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Chf Clinical Develop Officer | Sell | 1,484 | $32.20 | $47,779.90 | -2.4% | -0.6% | +159.2% | |
| Jan 16, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Chf Clinical Develop Officer | Sale+OE | 6,523 | $32.79 | $213,889.17 | -10.0% | -12.2% | +136.5% | |
| Feb 2, 2024 | IONS Ionis Pharmaceuticals Inc | EVP, Chf Clinical Develop Officer | Sell | 2,071 | $49.59 | $102,700.89 | -4.0% | -13.4% | -35.9% | |
| Jan 17, 2024 | IONS Ionis Pharmaceuticals Inc | EVP, Chf Clinical Develop Officer | Sale+OE | 5,482 | $50.42 | $276,385.99 | -10.3% | -19.0% | -37.1% |